(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(-0.23%) $83.66
(-1.16%) $1.619
(0.10%) $2 349.60
(-0.07%) $27.52
(0.25%) $924.40
(0.35%) $0.935
(0.54%) $11.01
(0.09%) $0.800
(0.00%) $92.17
Live Chart Being Loaded With Signals
Daré Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in the identifying, developing, and marketing products for women's health in the United States...
Stats | |
---|---|
本日の出来高 | 171 986 |
平均出来高 | 443 592 |
時価総額 | 30.77M |
EPS | $0 ( 2024-03-28 ) |
次の収益日 | ( $-0.0600 ) 2024-05-09 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.870 |
ATR14 | $0.00200 (0.66%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-12 | Fair John A | Buy | 290 000 | Employee Stock Option (right to buy) |
2024-03-12 | Johnson Sabrina Martucci | Buy | 750 000 | Employee Stock Option (right to buy) |
2024-03-12 | Haring-layton Mardee | Buy | 290 000 | Employee Stock Option (right to buy) |
2024-01-26 | Haring-layton Mardee | Sell | 3 500 | Employee Stock Option (right to buy) |
2024-01-26 | Haring-layton Mardee | Sell | 30 000 | Employee Stock Option (right to buy) |
INSIDER POWER |
---|
78.74 |
Last 91 transactions |
Buy: 10 072 923 | Sell: 492 500 |
ボリューム 相関
Dare Bioscience Inc 相関
10 最も負の相関 | |
---|---|
LEDS | -0.902 |
MPRA | -0.871 |
MTEK | -0.865 |
OBNK | -0.861 |
PUCKU | -0.841 |
MTEM | -0.838 |
BWMX | -0.836 |
NCAC | -0.834 |
MTCR | -0.832 |
CCRC | -0.83 |
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Dare Bioscience Inc 相関 - 通貨/商品
Dare Bioscience Inc 財務諸表
Annual | 2023 |
収益: | $2.81M |
総利益: | $2.77M (98.63 %) |
EPS: | $-0.350 |
FY | 2023 |
収益: | $2.81M |
総利益: | $2.77M (98.63 %) |
EPS: | $-0.350 |
FY | 2022 |
収益: | $10.00M |
総利益: | $9.95M (99.52 %) |
EPS: | $4.81 |
FY | 2021 |
収益: | $0.00 |
総利益: | $0.00 (0.00 %) |
EPS: | $-0.630 |
Financial Reports:
No articles found.
Dare Bioscience Inc
Daré Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in the identifying, developing, and marketing products for women's health in the United States. It develops therapies in the areas of contraception, fertility, and sexual and vaginal health. The company's product includes XACIATO, a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in female patients 12 years of age and older. Its products in advanced clinical development include Ovaprene, a hormone-free monthly vaginal contraceptive; and Sildenafil Cream, a cream formulation of sildenafil for topical administration to the vulva and vagina for treatment of female sexual arousal disorder. The company's Phase 1-ready products are DARE-HRT1, a combination of bio-identical estradiol and progesterone intravaginal ring for the treatment of vasomotor symptoms in hormone therapy; DARE-VVA1, a vaginally delivered formulation of tamoxifen to treat vulvar and vaginal atrophy in patients with hormone-receptor positive breast cancer; and DARE-FRT1, an intravaginal ring containing bio-identical progesterone for the prevention of preterm birth and broader luteal phase support as part of an in vitro fertilization treatment plan, as well as DARE-PTB1, an intravaginal ring containing bio-identical progesterone for the prevention of preterm birth. Its products in pre-clinical stage include DARE-LARC1, a combination product designed to provide reversible contraception; ADARE-204 and ADARE-214, an injectable formulations of etonogestrel to provide contraception over 6-month and 12-month periods; and DARE-RH1, a non-hormonal contraception for men and women. The company entered into license agreement with Organon & Co. and Organon International GmbH to commercialize XACIATO. Daré Bioscience, Inc. is headquartered in San Diego, California.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。